Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma

首页 > 成果 > 详情

认领

导出

Link by 万方学术期刊

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Zhou, Ruolan;Fan, Shaoyu;Zhang, Minmin;Zhang, Qingsen;Hu, Jian;...

通讯作者：

Chen, Xin;Zheng, Canhui;Shen, Aijun

作者机构：

[Chen, Xin; Zhou, Ruolan; Fan, Shaoyu] Wuhan Polytech Univ, Sch Biol & Pharmaceut Engn, Wuhan 430023, Hubei, Peoples R China.

[Hu, Jian; Wang, Mingping; Wang, Chongqing; Zheng, Canhui; Zhu, Ju; Zhang, Qingsen; Zhou, Ruolan; Fan, Shaoyu] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.

[Zhang, Minmin; Shen, Aijun] Chinese Acad Sci, SIMM, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China.

通讯机构：

[Chen, Xin] W

[Zheng, Canhui] S

[Shen, Aijun] C

Wuhan Polytech Univ, Sch Biol & Pharmaceut Engn, Wuhan 430023, Hubei, Peoples R China.

Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.

语种：

英文

关键词：

Anti-tumor agents;Bcl-2 inhibitors;Dualtarget inhibitors;HDAC inhibitors;HDAC6 inhibitors;Multiple myeloma

期刊：

Bioorganic & Medicinal Chemistry Letters

ISSN：

0960-894X

年：

2019

卷：

期：

页码：

349-352

DOI：

10.1016/j.bmcl.2018.12.052

基金类别：

We thank the Shanghai Rising-Star Program of China ( 16QA1404800 ), the State Key laboratory of Drug Research of China ( SIMM1601KF-01 ), and the National Natural Science Foundation of China (Grant Nos. 21572266 and 81673472 ) for financial support.

机构署名：

本校为第一且通讯机构

院系归属：

生命科学与技术学院

摘要：

Multiple myeloma (MM) is the second most common haematological malignancy. Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action. Therefore novel drugs are in urgent need in clinic. Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. In this study, a series of Bcl-2/HDAC dual-targ...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问